Be informedto choose the best path for you

Active Surveillance or Treatment?For Prostate Cancer
OUR NEXT VIRTUAL MEETING
The Goal Isn’t Finding More Prostate Cancer—It’s Finding the Right Prostate Cancer
Join Jason M. Hafron, MD for a different way of thinking about prostate cancer diagnosis: what if better testing could spare some men an unnecessary biopsy and a diagnosis of low-risk cancer that may never cause harm? Dr. Hafron will discuss how blood and urine biomarkers, alongside MRI, may help identify cancers that deserve closer attention while reducing overdiagnosis. We’ll also explore what this changing approach could mean for men considering or already on Active Surveillance.
EXPLORE ASPI RESOURCES
Explore a few of ASPI’s interactive tools and educational resources designed to help men on Active Surveillance feel more informed and supported.
WE ARE THRIVERS

Thrainn’s Story
In my opinion, my greatest personal accomplishment was to undertake extensive research on my own, followed by choosing AS. When I was diagnosed with PC at the age of 61, my doctors strongly recommended that I undergo traditional treatment. Surgery was at the top of the list.

Mark's Story
Eighteen years ago, I was diagnosed with Gleason 6 prostate cancer at the age of 55 – and, against the advice of five medical professionals (including my wife, a nurse practitioner) I chose not to have intervention.
Years on Active Surveillance
| Patients | Years | Months |
|---|---|---|
| Mark Lichty | 21 | 5 |
| Bill Manning | 17 | 4 |
| Howard Wolinsky | 15 | 5 |
| Geoff McLennan | 14 | 7 |
| David King Keller | 12 | 5 |
The following ASPI directors have now entered treatment:
- Thrainn Torvaldsson after 14 years of Active Surveillance.
We share this to help reassure you about the choice you have made—or may be considering. Active Surveillance is chosen not only to avoid or delay side effects, but also to allow time for treatments to evolve.
In Thrainn’s case, our Icelandic board member who was diagnosed nearly two decades ago, waiting meant options improved. Had he been treated at diagnosis, he would likely have received more aggressive treatment than what was ultimately needed years later—thanks to advances in care over time.
LEARN ABOUT THE PREDICT PROSTATE TOOL
Predict Prostate is an evidence-based tool for men with early, non-metastatic prostate cancer who are weighing Active Surveillance and treatment. It provides personalized estimates based on your cancer details, age, and overall health, helping you compare options more realistically and calmly.
Articles and Resources

Exploring the Use of Complementary Therapies Alongside Active Surveillance for Prostate Cancer
Telka Martin explores yoga, mindfulness, nutrition, exercise, supplements, and other ways to support well-being alongside Active Surveillance, while distinguishing general health benefits from cancer control.

What Should You Do If Your PSA Goes Up?
Why one higher PSA result rarely tells the whole story. If you’re on Active Surveillance, seeing your PSA go up can be worrying. It’s easy to look at one higher … Read More

The Knowledge to Participate in the Decision: One Patient’s ASPI Story
Sometimes the clearest way to understand the value of good information is through the experience of someone who has had to use it. The following story was shared with ASPI … Read More


